Summary & Overview
CPT 3517F: Hepatitis B Screening and Interpretation Before First TNF Inhibitor Course
CPT code 3517F denotes documentation that a provider performed hepatitis B virus (HBV) screening and interpreted results within the year before a patient with inflammatory bowel disease (IBD) received a first course of tumor necrosis factor (TNF) inhibitor therapy. This code captures an important safety step in biologic initiation: identifying prior or current HBV infection to reduce the risk of viral reactivation when starting immunosuppressive therapy. Nationally, consistent capture of this screening event supports patient safety initiatives and quality measurement for IBD treatment pathways.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what CPT code 3517F represents, where the service is typically delivered, and why it is clinically relevant. The publication outlines common billing contexts and reporting considerations, and it highlights benchmarks and policy updates relevant to pre-biologic infectious disease screening. The content provides clinical context for why HBV screening matters prior to TNF inhibitor initiation, and it explains what information is included in the code versus what data are not available in the input.
This national summary is intended for clinicians, coding professionals, payers, and policy analysts seeking clear, actionable information about documentation and coding for HBV screening before initiating TNF inhibitor therapy in IBD patients.
Billing Code Overview
CPT code 3517F documents that the provider has screened a patient for hepatitis B virus (HBV) and interpreted the results within one year prior to a patient with inflammatory bowel disease (IBD) receiving a first course of tumor necrosis factor (TNF) inhibitor therapy.
Service type: Pre-treatment infectious disease screening and test interpretation
Typical site of service: Outpatient clinic or infusion/infusion-preparation setting where TNF inhibitor therapy is initiated
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with established inflammatory bowel disease presents to a gastroenterology clinic for assessment prior to initiation of first-line biologic therapy with a tumor necrosis factor (TNF) inhibitor. The clinic visit includes a focused history, review of prior laboratory testing, and ordering or documentation of hepatitis B virus (HBV) screening tests (HBsAg, anti-HBs, and anti-HBc) with interpretation documented in the medical record. If screening was done within the prior 12 months, the provider reviews and documents results and their clinical interpretation, including evidence of immunity, prior exposure, or active infection. Documentation also addresses whether antiviral prophylaxis is indicated based on serology and planned TNF inhibitor therapy. Typical workflow steps: order HBV serologies (if not already available within 12 months), receive lab results, interpret results in context of TNF inhibitor risk, document interpretation and plan in chart, and proceed with biologic initiation if appropriate. Typical site of service: outpatient gastroenterology clinic or infusion center intake visit where initiation of biologic therapy is being planned.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
52 | Reduced services | Use when a service is partially reduced or eliminated at the physician’s discretion (e.g., partial visit components completed before therapy initiation). |
53 | Discontinued procedure | Use when the planned pre-biologic visit or associated testing is started but discontinued due to patient factors or contraindication. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207VG0300X | Gastroenterology | Gastroenterologists commonly assess IBD patients and order/interpret HBV screening prior to TNF inhibitor therapy. |
207RH0000X | Rheumatology | Rheumatologists initiate TNF inhibitors for rheumatologic indications and perform pre-biologic HBV screening. |
2080P0205X | Infectious Disease | Infectious disease specialists provide consultation for complex HBV results and prophylaxis decisions. |
208D00000X | Family Medicine | Primary care clinicians may document HBV screening and interpretation prior to specialist-directed TNF inhibitor therapy. |
207K00000X | Allergy & Immunology | Allergists/immunologists involved in biologic management may document HBV screening before TNF inhibitors. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
K50.90 | Crohn's disease, unspecified, without complications | Crohn disease is a common inflammatory bowel disease indication for TNF inhibitor therapy requiring pre-treatment HBV screening. |
K51.90 | Ulcerative colitis, unspecified, without complications | Ulcerative colitis is another IBD indication for TNF inhibitors; HBV screening is required before first course. |
B18.1 | Chronic viral hepatitis B without delta-agent | Active chronic HBV is directly relevant because TNF inhibitors can cause reactivation; documentation of status is essential. |
B19.10 | Unspecified viral hepatitis B without hepatic coma | Acute or unspecified HBV infection affects eligibility and management prior to biologic therapy. |
Z79.899 | Other long term (current) drug therapy | Represents ongoing therapies (including immunosuppressives) that influence HBV risk assessment prior to TNF inhibitor initiation. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
36415 | Collection of venous blood by venipuncture | Used to obtain specimens for HBV serologies ordered prior to TNF inhibitor initiation. |
80053 | Comprehensive metabolic panel | Commonly ordered alongside HBV screening to evaluate baseline liver function before biologic therapy. |
86663 | Hepatitis B surface antigen (HBsAg) | Direct HBV screening assay typically performed as part of the required testing. |
86706 | Hepatitis B core antibody (anti-HBc) | Component of HBV screening to detect prior exposure; informs risk assessment for reactivation. |
86707 | Hepatitis B surface antibody (anti-HBs) | Assesses immunity status as part of pre-biologic evaluation. |